Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 98
Filter
1.
J Biosci ; 492024.
Article in English | MEDLINE | ID: mdl-38920106

ABSTRACT

Noradrenaline (NA) and serotonin (5-HT) induce nociception and antinociception. This antagonistic effect can be explained by the dose and type of activated receptors. We investigated the existence of synergism between the noradrenergic and serotonergic systems during peripheral antinociception. The paw pressure test was performed in mice that had increased sensitivity by intraplantar injection of prostaglandin E2 (PGE2). Noradrenaline (80 ng) administered intraplantarly induced an antinociceptive effect, that was reversed by the administration of selective antagonists of serotoninergic receptors 5-HT1B isamoltan, 5-HT1D BRL15572, 5-HT2A ketanserin, 5-HT3 ondansetron, but not by selective receptor antagonist 5-HT7 SB-269970. The administration of escitalopram, a serotonin reuptake inhibitor, potentiated the antinociceptive effect at a submaximal dose of NA. These results, indicate the existence of synergism between the noradrenergic and serotonergic systems in peripheral antinociception in mice.


Subject(s)
Norepinephrine , Receptors, Serotonin , Serotonin Antagonists , Serotonin , Animals , Mice , Norepinephrine/metabolism , Serotonin/metabolism , Serotonin Antagonists/pharmacology , Male , Receptors, Serotonin/metabolism , Dinoprostone/metabolism , Citalopram/pharmacology , Nociception/drug effects , Analgesics/pharmacology , Ondansetron/pharmacology , Ketanserin/pharmacology , Pain/drug therapy , Pain/metabolism , Selective Serotonin Reuptake Inhibitors/pharmacology
2.
Toxicon ; 218: 57-65, 2022 Oct 30.
Article in English | MEDLINE | ID: mdl-36113683

ABSTRACT

Rhinella marina toad is abundant in Brazil. Its poison contains cardiac glycosides called bufadienolides, which are extensively investigated for their bioactivity. Our aim was to characterize the vasoactivity of Rhinella marina poison (RmP) on the aorta of male Wistar rats. For this, the RmP was first collected and processed to obtain an alcoholic extract. To determine cardiovascular effects of RmP, we performed in vivo tests by administering RmP intravenously in doses of 0.1-0.8 mg/kg. Vascular reactivity was also performed through concentration-response curves to RmP (10 ng/mL to 200 µg/mL) in aortic segments with and without endothelium. RmP induced a concentration-dependent contraction in rat aorta which was partly endothelium-mediated. Nitric oxide contributes with this response in view that incubation with L-NAME increased the contractile response. Additionally, treatment with indomethacin [cyclooxygenase, (COX) inhibitor], nifedipine (L-type voltage-gated calcium channels blocker), and BQ-123 (ETA receptors antagonist) decreased maximum response, and ketanserin (5-HT2 receptors antagonist) decreased pEC50, suggesting active participation of these pathways in the contractile response. On the other hand, apocynin (NADPH oxidase inhibitor) did not alter contractility. Incubation with prazosin (α1-adrenergic receptor antagonist) abolished the contractile response, suggesting that the RmP-induced contraction is dependent on the adrenergic pathway. In the Na+/K+ ATPase protocol, a higher Emax was observed in the RmP experimental group, suggesting that RmP potentiated Na+/K+ATPase hyperpolarizing response. When this extract was injected (i.v.) in vivo, increase in blood pressure and decrease in heart rate were observed. The results were immediate and transitory, and occurred in a dose-dependent manner. Overall, these data suggest that the poison extract of R. marina toad has an important vasoconstrictor action and subsequent vasopressor effects, and its use can be investigated to some cardiovascular disorders.


Subject(s)
Bufanolides , Poisons , Adenosine Triphosphatases/metabolism , Adenosine Triphosphatases/pharmacology , Adrenergic Agents/pharmacology , Adrenergic Antagonists/pharmacology , Animals , Bufanolides/toxicity , Bufo marinus/metabolism , Calcium Channels , Endothelium, Vascular , Hemodynamics , Indomethacin/pharmacology , Ketanserin/pharmacology , Male , Methanol/pharmacology , NADPH Oxidases , NG-Nitroarginine Methyl Ester , Nifedipine/pharmacology , Nitric Oxide/metabolism , Prazosin/pharmacology , Prostaglandin-Endoperoxide Synthases/metabolism , Rats , Rats, Wistar , Serotonin/pharmacology , Vasoconstrictor Agents
3.
Sci Rep ; 11(1): 19176, 2021 09 28.
Article in English | MEDLINE | ID: mdl-34584123

ABSTRACT

Biogenic amines play an important role in the regulation of appetitive responses in insects. Among them, serotonin (5-HT) regulates feeding-related processes in numerous insect species. In carpenter ants, 5-HT administration has been shown to depress feeding behavior, thus opening the possibility of using 5-HT modulation in control strategies against those species considered as pest. Here we studied if administration of a 5-HT antagonist, ketanserin, promotes feeding of a sucrose solution and a toxic bait in carpenter ants Camponotus mus. We found that 3 h after a single oral administration of ketanserin, the mass of sucrose solution consumed by carpenter ants increased significantly. A similar effect was found after a chronic administration that lasted 5 days. Yet, ketanserin did neither affect the intake rates nor the activity of the pharyngeal pump that mediates feeding dynamics. In addition, ketanserin promoted the consumption of a toxic bait based on boric acid. Our results thus show that feeding motivation and consumption of both sucrose solution and a toxic bait can be enhanced via prior administration of ketanserin. We discuss the possible mechanisms underlying these effects and conclude that understanding basic physiological and neural principles that underlie feeding motivation allows establishing more efficient control strategies for pest insects.


Subject(s)
Ants/drug effects , Appetitive Behavior/drug effects , Insect Control/methods , Insecticides , Serotonin Antagonists/administration & dosage , Animals , Ants/physiology , Appetitive Behavior/physiology , Boric Acids , Ketanserin/administration & dosage , Serotonin/metabolism , Sucrose
4.
Respir Physiol Neurobiol ; 294: 103768, 2021 12.
Article in English | MEDLINE | ID: mdl-34343692

ABSTRACT

Acute intermittent hypoxia (AIH) modifies the functioning of the respiratory network, causing respiratory motor facilitation in anesthetized animals and a compensatory increase in pulmonary ventilation in freely behaving animals. However, it is still unclear whether the ventilatory facilitation induced by AIH in unanesthetized animals is associated with changes in the respiratory pattern. We found that Holtzman male rats (80-150 g) exposed to AIH (10 × 6% O2 for 30-40 s every 5 min, n = 9) exhibited a prolonged (30 min) increase in baseline minute ventilation (P < 0.05) compared to control animals (n = 13), combined with the occurrence of late expiratory peak flow events, suggesting the presence of active expiration. The increase in ventilation after AIH was also accompanied by reductions in arterial CO2 and body temperature (n = 5-6, P < 0.05). The systemic treatment with ketanserin (a 5-HT2 receptor antagonist) before AIH prevented the changes in ventilation and active expiration (n = 11) but potentiated the hypothermic response (n = 5, P < 0.05) when compared to appropriate control rats (n = 13). Our findings indicate that the ventilatory long-term facilitation elicited by AIH exposure in unanesthetized rats is linked to the generation of active expiration by mechanisms that may depend on the activation of serotonin receptors. In contrast, the decrease in body temperature induced by AIH may not require 5-HT2 receptor activation.


Subject(s)
Hypoxia/physiopathology , Ketanserin/pharmacology , Pulmonary Ventilation/physiology , Respiratory Mechanics/physiology , Serotonin 5-HT2 Receptor Antagonists/pharmacology , Animals , Disease Models, Animal , Male , Pulmonary Ventilation/drug effects , Rats , Rats, Sprague-Dawley , Respiratory Mechanics/drug effects , Tidal Volume/physiology
5.
Article in English | MEDLINE | ID: mdl-31676464

ABSTRACT

Ketamine has addictive potential, a troublesome fact due to its promising use as a therapeutic drug. An important phenomenon associated with drug addiction is behavioral sensitization, usually characterized as augmented locomotion. However, other behaviors may also be susceptible to sensitization, and/or interfere with locomotor activity. Thus, this study drew a comprehensive behavioral 'profiling' in an animal model of repeated administration of ketamine. Adult Swiss mice received single daily ketamine injections (30 or 50 mg/Kg, i.p.), which were followed by open field testing for 7 days (acquisition period, ACQ). A ketamine challenge (sensitization test, ST) was carried out after a 5-day withdrawal. Locomotion, rearing, grooming, rotation and falling were assessed during ACQ and ST. All behaviors were affected from the first ACQ day onwards, with no indication of competition between locomotion and the other behaviors. Only locomotion in response to 30 mg/Kg of ketamine both escalated during ACQ and expressed increased levels at ST, evidencing development and expression of locomotor sensitization. Considering the involvement of serotonin 5HT(2) and dopamine D(2) receptors on addiction mechanisms, we further tested the involvement of these receptors in ketamine-induced sensitization. Ketanserin (5HT2 antagonist, 3 mg/Kg, s.c.) prevented ketamine-evoked development of locomotor sensitization. However, ketanserin pretreatment during ACQ failed to inhibit its expression during ST. Raclopride (D2 antagonist, 0.5 mg/Kg, s.c.) evoked less robust reductions in locomotion but prevented the development of ketamine-evoked sensitization. Pretreatment during ACQ further inhibited the expression of sensitization during ST. These results indicate that a partial overlap in serotonergic and dopaminergic mechanisms underlies ketamine-induced locomotor sensitization.


Subject(s)
Central Nervous System Sensitization/drug effects , Ketamine/pharmacology , Locomotion/drug effects , Receptors, Dopamine D2/physiology , Receptors, Serotonin, 5-HT2/physiology , Animals , Dose-Response Relationship, Drug , Female , Ketamine/antagonists & inhibitors , Ketanserin/pharmacology , Male , Mice , Raclopride/pharmacology , Stereotyped Behavior/drug effects
6.
Br J Cancer ; 122(2): 194-208, 2020 01.
Article in English | MEDLINE | ID: mdl-31819176

ABSTRACT

BACKGROUND: Although produced by several types of tumours, the role of serotonin on cancer biology is yet to be understood. METHODS: The effects of serotonin (5-HT) on human breast cancer cells proliferation, signalling pathways and metabolic profile were evaluated by cytometry, western blotting, qPCR, enzymology and confocal microscopy. RESULTS: Our results revealed that incubation of MCF-7 cells with 10 µM 5-HT increased cell growth rate by 28%, an effect that was prevented by the 5-HTR2A/C antagonist, ketanserin. Conversely, increasing concentrations of 5-HT promoted glucose consumption and lactate production by MCF-7 cells. We also showed that increased glucose metabolism is provoked by the upregulation of pyruvate kinase M2 (PKM2) isoform through 5-HTR2A/C-triggered activation of Jak1/STAT3 and ERK1/2 subcellular pathways. However, we noticed a decrease in the rate of produced lactate per consumed glucose as a function of the hormone concentration, suggesting a disruption of the Warburg effect. The latter effect is due to 5-HTR2A/C-dependent mitochondrial biogenesis and metabolism, which is triggered by adenylyl cyclase/PKA, enhancing the oxidation of lactate within these cells. CONCLUSIONS: We showed that serotonin, through 5-HTR2A/C, interferes with breast cancer cells proliferation and metabolism by triggering two distinct signalling pathways: Jak1/STAT3 that boosts glycolysis through upregulation of PKM2, and adenylyl cyclase/PKA that enhances mitochondrial biogenesis.


Subject(s)
Breast Neoplasms/genetics , Cell Proliferation/drug effects , Janus Kinase 1/genetics , STAT3 Transcription Factor/genetics , Adenylyl Cyclases/genetics , Apoptosis/drug effects , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Carrier Proteins/genetics , Cell Survival/drug effects , Female , Glucose/metabolism , Glycolysis/drug effects , Humans , Ketanserin/pharmacology , MAP Kinase Signaling System/genetics , MCF-7 Cells , Membrane Proteins/genetics , Mitochondria/drug effects , Mitochondria/metabolism , Serotonin/pharmacology , Thyroid Hormones/genetics , Thyroid Hormone-Binding Proteins
7.
J Diabetes Res ; 2017: 3159798, 2017.
Article in English | MEDLINE | ID: mdl-29675430

ABSTRACT

BACKGROUND: Diabetic foot ulcers are one disabling complication of diabetes mellitus. Pirfenidone (PFD) is a potent modulator of extracellular matrix. Modified diallyl disulfide oxide (M-DDO) is an antimicrobial and antiseptic agent. AIM: To evaluate efficacy of topical PFD + M-DDO in a randomized, double-blind trial versus ketanserin in the treatment of noninfected chronic DFU. METHODS: Patients received PFD + M-DDO or ketanserin for 6 months. Relative ulcer volume (RUV) was measured every month; biopsies were taken at baseline and months 1 and 2 for histopathology and gene expression analysis for COL-1α, COL-4, KGF, VEGF, ACTA2 (α-SMA), elastin, fibronectin, TGF-ß1, TGF-ß3, HIF-1α, and HIF-1ß. RESULTS: Reduction of median RUV in the PFD + M-DDO group was 62%, 89.8%, and 99.7% at months 1-3 and 100% from months 4 to 6. Ketanserin reduced RUV in 38.4%, 56%, 60.8%, 94%, 94.8%, and 100% from the first to the sixth month, respectively. Healing score improved 4.5 points with PFD + M-DDO and 1.5 points with ketanserin compared to basal value. Histology analysis revealed few inflammatory cells and organized/ordered collagen fiber bundles in PFD + M-DDO. Expression of most genes was increased with PFD + M-DDO; 43.8% of ulcers were resolved using PFD + M-DDO and 23.5% with ketanserin. CONCLUSION: PFD + M-DDO was more effective than ketanserin in RUV reduction.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Diabetic Foot/drug therapy , Pyridones/therapeutic use , Wound Healing/drug effects , Adult , Aged , Anti-Infective Agents/pharmacology , Anti-Infective Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Disulfides , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Ketanserin/pharmacology , Ketanserin/therapeutic use , Male , Middle Aged , Pyridones/pharmacology , Sulfinic Acids/pharmacology , Sulfinic Acids/therapeutic use , Treatment Outcome
8.
Brain Res ; 1643: 152-8, 2016 07 15.
Article in English | MEDLINE | ID: mdl-27150816

ABSTRACT

The tonic immobility (TI) response is an innate fear behavior associated with intensely dangerous situations, exhibited by many species of invertebrate and vertebrate animals. In humans, it is possible that TI predicts the severity of posttraumatic stress disorder symptoms. This behavioral response is initiated and sustained by the stimulation of various groups of neurons distributed in the telencephalon, diencephalon and brainstem. Previous research has found the highest Fos-IR in the posteroventral part of the medial nucleus of the amygdala (MEA) during TI behavior; however, the neurotransmission of this amygdaloid region involved in the modulation of this innate fear behavior still needs to be clarified. Considering that a major drug class used for the treatment of psychopathology is based on serotonin (5-HT) neurotransmission, we investigated the effects of serotonergic receptor activation in the MEA on the duration of TI. The results indicate that the activation of the 5HT1A receptors or the blocking of the 5HT2 receptors of the MEA can promote a reduction in fear and/or anxiety, consequently decreasing TI duration in guinea pigs. In contrast, blocking the 5HT1A receptors or activating the 5HT2 receptors in this amygdalar region increased the TI duration, suggesting an increase in fear and/or anxiety. These alterations do not appear to be due to a modification of spontaneous motor activity, which might non-specifically affect TI duration. Thus, these results suggest a distinct role of the 5HT receptors in the MEA in innate fear modulation.


Subject(s)
Corticomedial Nuclear Complex/physiology , Fear/physiology , Immobility Response, Tonic , Receptor, Serotonin, 5-HT1A/physiology , Receptor, Serotonin, 5-HT2A/physiology , 8-Hydroxy-2-(di-n-propylamino)tetralin/administration & dosage , Animals , Anxiety/physiopathology , Corticomedial Nuclear Complex/drug effects , Fear/drug effects , Guinea Pigs , Immobility Response, Tonic/drug effects , Ketanserin/administration & dosage , Male , Serotonin 5-HT1 Receptor Agonists/administration & dosage , Serotonin 5-HT2 Receptor Antagonists/administration & dosage
9.
Pharmacol Rep ; 68(2): 434-42, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26922550

ABSTRACT

BACKGROUND: The purpose of this study was to determine the role of spinal 5-HT2A, 5-HT2B and 5-HT2C receptors in the development and maintenance of formalin-induced long-lasting secondary allodynia and hyperalgesia in rats, as well as their expression in the dorsal root ganglia (DRG) during this process. METHODS: 0.5-1% formalin was used to produce long-lasting secondary allodynia and hyperalgesia in rats. Western blot was used to determine 5-HT2 receptors expression in DRG. RESULTS: Formalin (0.5-1%) injection produced long-lasting (1-12 days) secondary allodynia and hyperalgesia in both ipsilateral and contralateral hind paws. Intrathecal pre-treatment or post-treatment with the 5-HT2 receptor agonist, DOI (1-10nmol), increased 0.5% formalin-induced secondary allodynia and hyperalgesia in both paws. In contrast, intrathecal pre-treatment with the selective 5-HT2A (ketanserin 1-100nmol), 5-HT2B (RS 127445 1-100nmol) or 5-HT2C (RS 102221 1-100nmol) receptor antagonists prevented and reversed, respectively, 1% formalin-induced secondary allodynia and hyperalgesia in both paws. Likewise, the pronociceptive effect of DOI (10nmol) was blocked by ketanserin, RS 127445 or RS 102221 (0.01nmol). 5-HT2A/2B/2C receptors were expressed in DRG of naïve rats. Formalin injection (1%) increased bilaterally 5-HT2A/2B receptors expression in DRG. In contrast, formalin injection decreased 5-HT2C receptors expression bilaterally in DRG. CONCLUSION: Data suggest that spinal 5-HT2A/2B/2C receptors have pronociceptive effects and participate in the development and maintenance of formalin-induced long-lasting hypersensitivity. These receptors are expressed in DRG and their expression is modulated by formalin.


Subject(s)
Formaldehyde/pharmacology , Hyperalgesia/chemically induced , Hyperalgesia/metabolism , Receptors, Serotonin, 5-HT2/metabolism , Spinal Cord/metabolism , Animals , Female , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Ketanserin/pharmacology , Pain Measurement/methods , Pyrimidines/pharmacology , Rats , Rats, Wistar , Spinal Cord/drug effects , Spiro Compounds/pharmacology , Sulfonamides/pharmacology
10.
Eur J Pharmacol ; 767: 94-7, 2015 Nov 15.
Article in English | MEDLINE | ID: mdl-26460149

ABSTRACT

The role of serotonin (5-HT) in nociception will vary according to the subtypes of receptors activated. When administered peripherally, it induces pain in humans and in rats by activation of 5-HT1, 5-HT2 and 5-HT3 receptors. In addition, endogenous 5-HT produced in situ, is involved in the nociceptive response induced by formalin in rat's paw inflammation, possibly via 5-HT3 receptors. Moreover, it has been shown that 5-HT released in the dorsal horn of the spinal cord by stimulation of the periaqueductal gray causes activation of inhibitory interneurons, resulting in inhibition of spinal neurons. In the present study we evaluated the effect of serotonin and its receptors at peripheral antinociception. The mice paw pressure test was used in animals that had increased sensitivity by an intraplantar injection of PGE2 (2 µg). We used selective antagonists of serotonin receptors (isamoltan 5-HT1B, BRL 15572 5-HT1D, ketanserin 5-HT2A, ondansetron 5-HT3 and SB-269970 5-HT7). Administration of serotonin into the right hind paw (62.5, 125, 250 and 500 ng and 1 µg) produced a dose-dependent peripheral mechanical antihyperalgesic effect of serotonin in mice. Selective antagonists for 5-HT1B, 5-HT2A, 5-HT3 receptors at doses of 0.1, 1 and 10 µg, reversed the antihyperalgesic effect induced by 250 ng serotonin. In contrast, selective antagonists for 5-HT1D and 5-HT7 receptors were unable to reverse the antihyperalgesic effect induced by serotonin. These results demonstrated for the first time, the peripheral mechanical antihyperalgesic effect of serotonin, and participation of 5-HT1B, 5-HT2A and 5-HT3 receptors in this event.


Subject(s)
Hyperalgesia/prevention & control , Pain Measurement/drug effects , Receptors, Serotonin/metabolism , Serotonin/pharmacology , Animals , Biphenyl Compounds/pharmacology , Dinoprostone , Dose-Response Relationship, Drug , Hyperalgesia/chemically induced , Ketanserin/pharmacology , Male , Mice , Ondansetron/pharmacology , Phenols/pharmacology , Piperazines/pharmacology , Propanolamines/pharmacology , Serotonin Antagonists/pharmacology , Sulfonamides/pharmacology
11.
Biomed Res Int ; 2015: 686424, 2015.
Article in English | MEDLINE | ID: mdl-26146627

ABSTRACT

Different analgesic combinations with caffeine have shown this drug to be capable of increasing the analgesic effect. Many combinations with nonsteroidal anti-inflammatory drugs (NSAIDs) have been carried out, but, in regard to opioids, only combinations with morphine and tramadol have been reported. The antinociceptive synergism mechanism of these combinations is not well understood. The purpose of the present study was to determine the participation of spinal and supraspinal opioidergic and serotonergic systems in the synergic effect of the tramadol+caffeine combination in the rat formalin test. At the supraspinal level, the opioid antagonist, naloxone, completely reversed the effect of the drug combination, whereas ketanserin, a 5-HT2 receptor antagonist, inhibited the effect by 60%; however, ondansetron, a 5-HT3 receptor antagonist, did not alter the combination effect. When the antagonists were intrathecally administered, there was a significant reduction in all tramadol-caffeine combination effects. With respect to tramadol alone, there was significant participation of the opioid system at the supraspinal level, whereas it was the serotonergic system that participated at the spinal level by means of the two receptors studied. In conclusion, the tramadol+caffeine combination synergically activated the opioid and serotonergic systems at the supraspinal level, as well as at the spinal level, to produce the antinociception.


Subject(s)
Caffeine/administration & dosage , Drug Synergism , Pain/drug therapy , Tramadol/administration & dosage , Analgesics, Opioid/metabolism , Animals , Dose-Response Relationship, Drug , Ketanserin/administration & dosage , Naloxone/administration & dosage , Ondansetron/administration & dosage , Pain/physiopathology , Pain Measurement/drug effects , Rats
12.
Neuroscience ; 232: 169-81, 2013 Mar 01.
Article in English | MEDLINE | ID: mdl-23219842

ABSTRACT

The role of 5-HT2A/2B/2C receptors in formalin-induced secondary allodynia and hyperalgesia in rats was assessed. Formalin produced acute nociceptive behaviors (flinching and licking/lifting) followed by long-term secondary mechanical allodynia and hyperalgesia. Pre-treatment for five consecutive days with compound 48/80 (1, 3, 10, 10, and 10 µg/paw) prevented formalin-induced secondary allodynia and hyperalgesia. Ipsilateral, but not contralateral, peripheral pre-treatment (nmol/paw) with the 5-HT2 receptor agonist DOI (3-30), 5-HT (10-100) or fluoxetine (0.3-3) significantly increased 0.5% formalin-induced secondary allodynia and hyperalgesia in both paws. The pronociceptive effect of DOI (10 nmol/paw), 5-HT (100 nmol/paw) and fluoxetine (1 nmol/paw) was blocked by selective 5-HT2A (ketanserin), 5-HT2B (RS-127445), and 5-HT2C (RS-102221) receptor antagonists. Furthermore, ipsilateral pre-treatment (nmol/paw) with ketanserin (1, 10, and 100), RS-127445 (0.01, 0.1 and 1) or RS-102221 (1, 10 and 100) prevented while post-treatment reversed 1% formalin-induced secondary allodynia and hyperalgesia in both paws. In marked contrast, contralateral injection of the greatest tested dose of 5-HT2A/2B/2C receptor antagonists did not modify long-lasting secondary allodynia and hyperalgesia. These results suggest that 5-HT released from mast cells after formalin injection sensitizes primary afferent neurons via 5-HT2A/2B/2C receptors leading to the development and maintenance of secondary allodynia and hyperalgesia.


Subject(s)
Formaldehyde/toxicity , Hyperalgesia/chemically induced , Hyperalgesia/metabolism , Receptor, Serotonin, 5-HT2A/metabolism , Receptor, Serotonin, 5-HT2B/metabolism , Receptor, Serotonin, 5-HT2C/metabolism , Amphetamines/pharmacology , Analgesics/pharmacology , Animals , Dose-Response Relationship, Drug , Female , Fluoxetine/pharmacology , Hyperalgesia/drug therapy , Ketanserin/pharmacology , Pyrimidines/pharmacology , Rats, Wistar , Serotonin/administration & dosage , Serotonin Antagonists/pharmacology , Serotonin Receptor Agonists/pharmacology , Selective Serotonin Reuptake Inhibitors/pharmacology , Spiro Compounds/pharmacology , Sulfonamides/pharmacology , p-Methoxy-N-methylphenethylamine/pharmacology
13.
Cienc. enferm ; 19(1): 75-82, 2013. ilus
Article in Spanish | LILACS | ID: lil-684341

ABSTRACT

Objetivo. Determinar el costo-efectividad de la ketanserina vs sulfadiazina en el paciente con pie diabético. Material y método. Estudio de costo efectividad en pacientes con pie diabético, se integraron dos grupos, los manejados con ketanserina (n=50) y los manejados con sulfadiazina (n=30), se incluyeron a todos los que acudieron al servicio. El costo contempló los insumos para la curación y el medicamento. La efectividad se midió con la reducción de la lesión medida en centímetros y el porcentaje de pacientes curados. Se realizó análisis incremental. Resultados. El costo del centímetro cuadrado de curación en ketanserina es de $22,43 US y en sulfadiazina $120,44 US. La proyección del costo a 5000 pacientes con una lesión de 10 centímetros es $1.121.651 US en ketanserina y $6.021.787 US en sulfadiazina de plata. Conclusión. En el manejo del pie diabético la relación costo-efectividad de la ketanserina es mejor que la sulfadiazina.


Objective. Determine the cost-efectiveness of the ketanserin vs. sulfadiazine on the patient with diabetic foot. Methodology. Study of the cost efectiveness on patients with diabetic foot, there were integrated two groups; the ones managed with ketanserin (n=50), and the ones managed with sulfadiazine (n=30), all that came to the service were included. Te cost contemplates the inputs for the cure and the medication. Te efectiveness was measured with the reduction of the injury measured in centimeters and the cured patient’s percent. Sensitivity and incremental analysis was performed. Results. Te cost of square centimeter of healing in ketanserin is $22.43 US and in the sulfadiazine $120.44 US. Te cost of 5000 patients whit an 10 centimeter injury is $1,121,651 US in ketanserin and $6,021,787 US in sulfadiazine. Conclusion. Te relation cost-efectiveness of the ketanserin is better than the sulfadiazine one in the management of the diabetic foot.


Subject(s)
Female , Middle Aged , Ketanserin/economics , Ketanserin/therapeutic use , Diabetic Foot/drug therapy , Sulfadiazine/economics , Sulfadiazine/therapeutic use , Cost Efficiency Analysis , Family Practice , Mexico , Diabetic Foot/economics
14.
Learn Mem ; 19(12): 593-7, 2012 Nov 16.
Article in English | MEDLINE | ID: mdl-23161448

ABSTRACT

Latent inhibition (LI) is a decrement in learning performance that results from the nonreinforced pre-exposure of the to-be-conditioned stimulus, in both vertebrates and invertebrates. In vertebrates, LI development involves dopamine and serotonin; in invertebrates there is yet no information. We studied differential olfactory conditioning of the proboscis extension response in the honeybee Apis mellifera, and we compared LI in individuals treated with antagonists of biogenic amines (dopamine, octopamine, and serotonin). An antagonist of octopamine receptors and two antagonists of serotonin receptors showed LI disruption. We thus provide evidence that serotonin would participate in the regulation of LI in honeybees.


Subject(s)
Conditioning, Classical/physiology , Dopamine/metabolism , Extinction, Psychological/physiology , Inhibition, Psychological , Serotonin/metabolism , Analysis of Variance , Animals , Bees/physiology , Conditioning, Classical/drug effects , Dibenzazepines/pharmacology , Dopamine/pharmacology , Dopamine Antagonists/pharmacology , Ethylketocyclazocine/analogs & derivatives , Ethylketocyclazocine/pharmacology , Extinction, Psychological/drug effects , Fluphenazine/pharmacology , Habituation, Psychophysiologic/drug effects , Histamine H1 Antagonists/pharmacology , Imidazoles/pharmacology , Ketanserin/pharmacology , Methysergide/pharmacology , Odorants , Serotonin/pharmacology , Serotonin Antagonists/pharmacology , Smell/drug effects , Smell/physiology
15.
Behav Brain Res ; 235(1): 42-7, 2012 Nov 01.
Article in English | MEDLINE | ID: mdl-22800924

ABSTRACT

Several findings have pointed to the role of the dorsal periaqueductal gray (dPAG) serotonin 5-HT(1A) and 5-HT(2A-C) receptor subtypes in the modulation of defensive behavior in animals exposed to the elevated plus-maze (EPM). Besides displaying anxiety-like behavior, rodents also exhibit antinociception in the EPM. This study investigated the effects of intra-dPAG injections of 5-HT(1A) and 5-HT(2B/2C) receptor ligands on EPM-induced antinociception in mice. Male Swiss mice received 0.1 µl intra-dPAG injections of vehicle, 5.6 and 10 nmol of 8-OHDPAT, a 5-HT(1A) receptor agonist (Experiment 1), or 0.01, 0.03 and 0.1 nmol of mCPP, a 5-HT(2B/2C) receptor agonist (Experiment 2). Five minutes later, each mouse received an intraperitoneal injection of 0.6% acetic acid (0.1 ml/10 g body weight; nociceptive stimulus) and was individually confined in the open (OA) or enclosed (EA) arms of the EPM for 5 min, during which the number of abdominal writhes induced by the acetic acid was recorded. While intra-dPAG injection of 8-OHDPAT did not change open-arm antinociception (OAA), mCPP (0.01 nmol) enhanced it. Combined injections of ketanserin (10 nmol/0.1 µl), a 5-HT(2A/2C) receptor antagonist, and 0.01 nmol of mCPP (Experiment 3), selectively and completely blocked the OAA enhancement induced by mCPP. Although intra-dPAG injection of mCPP (0.01 nmol) also produced antinociception in EA-confined mice (Experiment 2), this effect was not confirmed in Experiment 3. Moreover, no other compound changed the nociceptive response in EA-confined animals. These results suggest that the 5-HT(2C) receptors located within the PAG play a role in this type of environmentally induced pain inhibition in mice.


Subject(s)
Analgesics/pharmacology , Maze Learning/physiology , Nociception/physiology , Periaqueductal Gray/physiology , Serotonin 5-HT2 Receptor Agonists/pharmacology , Serotonin 5-HT2 Receptor Agonists/physiology , 8-Hydroxy-2-(di-n-propylamino)tetralin/administration & dosage , 8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology , Acetic Acid/antagonists & inhibitors , Acetic Acid/pharmacology , Analgesics/administration & dosage , Animals , Dose-Response Relationship, Drug , Ketanserin/pharmacology , Male , Maze Learning/drug effects , Mice , Microinjections , Nociception/drug effects , Periaqueductal Gray/drug effects , Piperazines/administration & dosage , Piperazines/antagonists & inhibitors , Piperazines/pharmacology , Serotonin 5-HT1 Receptor Agonists/pharmacology , Serotonin 5-HT1 Receptor Agonists/physiology , Serotonin 5-HT2 Receptor Agonists/administration & dosage , Serotonin Antagonists/pharmacology
16.
Eur J Pharmacol ; 679(1-3): 68-74, 2012 Mar 15.
Article in English | MEDLINE | ID: mdl-22266492

ABSTRACT

Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is a phenolic compound present in several plants with claimed beneficial effects in prevention and treatment of disorders linked to oxidative stress and inflammation. In this study, we aimed to verify the possible antidepressant-like effect of acute oral administration of ferulic acid in the forced swimming test (FST) and tail suspension test (TST) in mice. Additionally, the mechanisms involved in the antidepressant-like action and the effects of the association of ferulic acid with the antidepressants fluoxetine, paroxetine, and sertraline in the TST were investigated. Ferulic acid produced an antidepressant-like effect in the FST and TST (0.01-10 mg/kg, p.o.), without accompanying changes in ambulation. The pretreatment of mice with WAY100635 (0.1 mg/kg, s.c., a selective 5-HT(1A) receptor antagonist) or ketanserin (5 mg/kg, i.p., a 5-HT(2A) receptor antagonist) was able to reverse the anti-immobility effect of ferulic acid (0.01 mg/kg, p.o.) in the TST. The combination of fluoxetine (5 mg/kg, p.o.), paroxetine (0.1 mg/kg, p.o.) or sertraline (1 mg/kg, p.o.) with a sub-effective dose of ferulic acid (0.001 mg/kg, p.o.) produced a synergistic antidepressant-like effect in the TST, without causing hyperlocomotion in the open-field test. Taken together, these results demonstrate that ferulic acid exerts antidepressant-like effect in the FST and TST in mice through modulation of the serotonergic system.


Subject(s)
Antidepressive Agents/pharmacology , Coumaric Acids/pharmacology , Selective Serotonin Reuptake Inhibitors/pharmacology , Serotonin 5-HT1 Receptor Antagonists/pharmacology , Serotonin 5-HT2 Receptor Antagonists/pharmacology , Animals , Coumaric Acids/agonists , Coumaric Acids/antagonists & inhibitors , Dose-Response Relationship, Drug , Drug Interactions , Fluoxetine/pharmacology , Immobility Response, Tonic/drug effects , Ketanserin/pharmacology , Male , Mice , Motor Activity/drug effects , Paroxetine/pharmacology , Piperazines/pharmacology , Pyridines/pharmacology , Receptor, Serotonin, 5-HT1A , Receptor, Serotonin, 5-HT2A , Sertraline/pharmacology
17.
Behav Brain Res ; 226(1): 50-5, 2012 Jan 01.
Article in English | MEDLINE | ID: mdl-21907244

ABSTRACT

Serotonin in the lateral septum has been implicated in the modulation of defense and hence in anxiety. However, it deserves investigation how changes in 5-HT-mechanisms in this area modulate defensive responses associated with specific subtypes of anxiety disorders. We evaluated the effects of intra-dorsolateral septum (DLS) injections of the preferential 5-HT(2A) receptor agonist DOI (8 and 16nmol), the 5-HT(2C) selective agonist MK-212 (0.1 and 1nmol) and the preferential 5-HT(2A) antagonist ketanserin (10 and 20nmol) in rats exposed to the elevated T-maze (ETM), a model which allows the measurement of two defensive responses: inhibitory avoidance and escape. These responses have been respectively related to generalized anxiety and panic disorder. All animals were tested in an open-field after the ETM for locomotor activity assessments. Results showed that intra-DLS DOI increased avoidance latencies, an anxiogenic effect. MK and ketanserin were without effect. Also, none of the drugs administered affected the escape performance. Ketanserin blocked the anxiogenic effect caused by DOI. No changes to locomotion were observed. The data suggests that DLS 5-HT(2A) receptors are involved in the control of inhibitory avoidance and that a failure in this mechanism may be of importance to the physiopathology of generalized anxiety.


Subject(s)
Anxiety/metabolism , Escape Reaction/physiology , Receptor, Serotonin, 5-HT2A/metabolism , Septum of Brain/metabolism , Amphetamines/pharmacology , Animals , Anxiety/physiopathology , Avoidance Learning/drug effects , Avoidance Learning/physiology , Escape Reaction/drug effects , Ketanserin/pharmacology , Male , Rats , Rats, Wistar , Septum of Brain/drug effects , Serotonin Antagonists/pharmacology , Serotonin Receptor Agonists/pharmacology
18.
Behav Brain Res ; 225(2): 547-53, 2011 Dec 01.
Article in English | MEDLINE | ID: mdl-21839779

ABSTRACT

Several lines of evidence support the involvement of serotonergic (5-HT) neurons of the median raphe nucleus (MRN) in anxiety-like behaviour. In this context, it is known that blockade of 5-HT(1A) somatodendritic autoreceptors in the midbrain raphe nuclei increases the firing rate of these neurons, disinhibiting 5-HT release in postsynaptic target areas such as amygdala, hippocampus and periaqueductal grey matter (PAG). However, while activation of 5-HT(1A) or 5-HT(2) receptors in forebrain targets such as the amygdala or hippocampus enhances anxiety-like behaviours in rodents, stimulation of both receptor subtypes in the midbrain PAG markedly reduces anxiety-like behaviour. In view of these findings, the present study investigated whether the anti-anxiety effects induced by pharmacological disinhibition of 5-HT neurons in the MRN are attenuated by the blockade of 5-HT(2) receptors within the PAG. Mice received combined intra-PAG injection with ketanserin (10 nmol/0.1 µl), a 5-HT(2) receptor antagonist, followed by intra-MRN injection of WAY-100635 (5.6 nmol/0.1 µl), a highly selective 5-HT(1A) receptor antagonist. They were then individually exposed to the elevated plus-maze (EPM), with the videotaped behavioural sessions subsequently scored for both conventional and ethological measures. The results confirmed that intra-MRN infusion of WAY100635 reduces behavioural indices of anxiety without significantly altering general activity measures, and further showed that this effect was completely blocked by intra-PAG pretreatment with an intrinsically-inactive dose of ketanserin. Together, these results suggest that 5HT(2) receptor populations located within the midbrain PAG play a significant role in the reduction of anxiety observed following disinhibition of 5-HT neurons in the MRN.


Subject(s)
Anti-Anxiety Agents/pharmacology , Ketanserin/pharmacology , Periaqueductal Gray/drug effects , Piperazines/pharmacology , Pyridines/pharmacology , Raphe Nuclei/drug effects , Serotonin Antagonists/pharmacology , Animals , Anti-Anxiety Agents/antagonists & inhibitors , Behavior, Animal/drug effects , Ketanserin/administration & dosage , Male , Maze Learning/drug effects , Mice , Microinjections/psychology , Piperazines/administration & dosage , Pyridines/administration & dosage , Serotonin Antagonists/administration & dosage
19.
Int J Neuropsychopharmacol ; 13(9): 1247-54, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20663269

ABSTRACT

The central nervous system control of food intake has been extensively studied, hence, several neurotransmitter systems regulating this function are now clearly identified, for example, the endocannabinoid and serotoninergic systems. The former stimulates feeding while the latter inhibits it. Oleamide (Ole) is a cannabimimetic molecule affecting both systems. In this work, we tested the orexigenic and anorectic potential of Ole when administered into the nucleus accumbens shell (NAcS), a brain region that has been related to the orexigenic effects of cannabinoids. Additionally, we tested if Ole administered into this nucleus affects the activity of the hypothalamic nuclei involved in feeding behaviour, just as other cannabinoids do. We found a hyperphagic effect of Ole that is mediated through CB1 activation. The combination of Ole and the CB1 antagonist, AM251, produced a hypophagia that was fully blocked by SB212084, a 5-HT2C receptor antagonist. We also show that blockade of 5-HT2C and 5-HT2A receptors in the NAcS stimulates food intake. Finally, the combination of Ole and AM251 activates hypothalamic nuclei, an effect also blocked by SB242084. In conclusion, we show, for the first time, that Ole administered into the NAcS has a dual effect on feeding behaviour, acting through cannabinoid and serotonin receptors. These effects probably result from a downstream interaction with the hypothalamus.


Subject(s)
Eating/drug effects , Feeding Behavior/drug effects , Nucleus Accumbens/drug effects , Oleic Acids/pharmacology , Receptor, Cannabinoid, CB1/metabolism , Serotonin 5-HT2 Receptor Antagonists/pharmacology , Aminopyridines/pharmacology , Animals , Feeding Behavior/physiology , Hyperphagia/chemically induced , Hypothalamus/drug effects , Hypothalamus/metabolism , Indoles/pharmacology , Ketanserin/pharmacology , Male , Motor Activity/drug effects , Nucleus Accumbens/metabolism , Oleic Acids/administration & dosage , Piperidines/pharmacology , Pyrazoles/pharmacology , Rats , Rats, Wistar , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Receptor, Cannabinoid, CB1/biosynthesis , Receptor, Serotonin, 5-HT2A/metabolism , Receptor, Serotonin, 5-HT2C/metabolism
20.
Neurosci Lett ; 479(2): 87-91, 2010 Jul 26.
Article in English | MEDLINE | ID: mdl-20478359

ABSTRACT

Chemical stimulation of the lateral nucleus of the habenula (LHb), an area implicated in the regulation of serotonergic activity in raphe nuclei, affects the acquisition of inhibitory avoidance and escape expression of rats submitted to the elevated T-maze test of anxiety. Here, we investigated whether facilitation of 5-HT-mediated neurotransmission in the dorsal periaqueductal gray (dPAG) accounts for the behavioral consequences in the elevated T-maze induced by chemical stimulation of the LHb. The dPAG in the midbrain, which is innervated by 5-HT fibers originating from the dorsal raphe nucleus (DRN), has been consistently implicated in the genesis/regulation of anxiety- and fear-related defensive responses. The results showed that intra-dPAG injection of WAY-100635 or ketanserin, 5-HT(1A) and 5-HT(2A/2C) receptor antagonists, respectively, counteracted the anti-escape effect caused by bilateral intra-LHb injection of kainic acid (60pmol/0.2microl). Ketanserin, but not WAY-100635, blocked kainic acid's facilitatory effect on inhibitory avoidance acquisition. Overall, the results suggest that the pathway connecting the LHb to the DRN is involved in the control of 5-HT release in the dPAG, and facilitation of 5-HT-mediated neurotransmission in the latter area distinctively impacts upon the expression of anxiety- and fear-related defensive behaviors. While stimulation of 5-HT(1A) receptors selectively affects escape performance, 5-HT(2A/2C) receptors modulate both inhibitory avoidance and escape.


Subject(s)
Avoidance Learning , Habenula/physiology , Periaqueductal Gray/physiology , Serotonin/physiology , Synaptic Transmission , Animals , Kainic Acid/pharmacology , Ketanserin/pharmacology , Male , Maze Learning/drug effects , Motor Activity/drug effects , Neurons/drug effects , Neurons/physiology , Periaqueductal Gray/drug effects , Piperazines/pharmacology , Pyridines/pharmacology , Rats , Rats, Wistar , Receptor, Serotonin, 5-HT1A/physiology , Receptor, Serotonin, 5-HT2A/physiology , Receptor, Serotonin, 5-HT2C/physiology , Serotonin 5-HT1 Receptor Antagonists , Serotonin 5-HT2 Receptor Antagonists
SELECTION OF CITATIONS
SEARCH DETAIL